"Texas Oncology is an independent private practice with more than 500 physicians and 210 locations across the state. Meeting the oncology needs of Texans for more than 35 years, the practice includes Texas Center for Proton Therapy, Texas Breast Specialists, Texas Oncology Surgical Specialists, and Texas Center for Interventional Surgery. As a lead participant in US Oncology Research, Texas Oncology played a role in the development of more than 100 FDA-approved therapies."

During the past decade, Texas Oncology-Paris conducted 22 clinical trials. In the 10-year time frame, 22 clinical trials started and 6 clinical trials were completed, i.e. on average, 27.3% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 2 clinical trials were completed. i.e. 15.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Texas Oncology-Paris" #1 sponsor was "Bristol-Myers Squibb" with 4 trials, followed by "Eli Lilly and Company" with 3 trials sponsored, "Pfizer" with 3 trials sponsored, "Eisai Inc." with 2 trials sponsored and "Hoffmann-La Roche" with 2 trials sponsored. Other sponsors include 12 different institutions and companies that sponsored additional 22 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Texas Oncology-Paris" #1 collaborator was "Merck Sharp & Dohme LLC" with 2 trials as a collaborator, "National Cancer Institute (NCI)" with 2 trials as a collaborator, "ICON Clinical Research" with 1 trials as a collaborator, "Janssen, LP" with 1 trials as a collaborator and "Medpace, Inc." with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Texas Oncology-Paris" are "Breast Cancer" (8 trials), "Non-small Cell Lung Cancer" (4 trials), "Non-Small Cell Lung Cancer" (3 trials), "Melanoma" (2 trials) and "Metastatic Breast Cancer" (2 trials). Many other conditions were trialed in "Texas Oncology-Paris" in a lesser frequency.

Most popular intervention types in "Texas Oncology-Paris" are "Drug" (23 trials), "Other" (5 trials), "Biological" (2 trials), "Device" (1 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Docetaxel" (4 trials), "Placebo" (4 trials), "Abemaciclib" (3 trials), "Paclitaxel" (3 trials) and "Carboplatin" (2 trials). Other intervention names were less common.

The vast majority of trials in "Texas Oncology-Paris" are 26 trials for "All" genders, 3 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Texas Oncology-Paris". undefined are not yet recruiting, 9 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 14 completed trials in Texas Oncology-Paris, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Texas Oncology-Paris, 3 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".